Compositions for Treating and/or Preventing Cancer

1 . A pharmaceutical composition comprising:

at least one compound selected from compounds having formula (I)

prodrugs thereof, pharmaceutically acceptable salts of any of the foregoing, and

pharmaceutically acceptable solvates of any of the foregoing;

at least one binder;

at least one disintegrant;

at least one other excipient; and

at least one component chosen from at least one lubricant and at least one surfactant.

2 - 3 . (canceled)

4 . The pharmaceutical composition claim 1 , wherein

the at least one binder is Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer);

the at least one disintegrant is croscarmellose sodium;

the at least one pharmaceutical excipient is mannitol; and

the at least one surfactant is Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate).

5 . The pharmaceutical composition of claim 4 , wherein:

the at least one compound is in an amount ranging from about 5 wt-% to about 25 wt-%;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount ranging from about 5 wt-% to about 25 wt-%;

the croscarmellose sodium is in an amount ranging from about 5 wt-% to about 25 wt-%;

the mannitol is in an amount ranging from about 20 wt-% to about 60 wt-%; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount ranging from about 1 wt-% to about 20 wt-%.

6 . (canceled)

7 . The pharmaceutical composition of claim 5 , wherein:

the at least one compound is in an amount of about 16.7 wt-%;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount of about 16.7 wt-%;

the croscarmellose sodium is in an amount of about 16.7 wt-%;

the mannitol is in an amount of about 41.67 wt-%; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount of about 8.33 wt-%.

8 . The pharmaceutical composition of claim 4 , wherein:

the at least one compound is in an amount ranging from about 30 mg to about 130 mg;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount ranging from about 30 mg to about 130 mg;

the croscarmellose sodium is in an amount ranging from about 30 mg to about 130 mg;

the mannitol is in an amount ranging from about 100 mg to about 300 mg; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount ranging from about 5 mg to about 75 mg.

9 . (canceled)

10 . The pharmaceutical composition of claim 8 , wherein:

the at least one compound is in an amount of about 80 mg;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount of about 80 mg;

the croscarmellose sodium is in an amount of about 80 mg;

the mannitol is in an amount of about 200 mg; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount of about 40 mg.

11 . The pharmaceutical composition of claim 4 , wherein:

the at least one compound is in an amount ranging from about 5 wt-% to about 25 wt-%;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount ranging from about 5 wt-% to about 25 wt-%;

the croscarmellose sodium is in an amount ranging from about 15 wt-% to about 55 wt-%;

the mannitol is in an amount ranging from about 5 wt-% to about 25 wt-%; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount ranging from about 5 wt-% to about 25 wt-%.

12 . (canceled)

13 . The pharmaceutical composition of claim 11 , wherein:

the at least one compound is in an amount of about 16.7 wt-%;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount of about 16.7 wt-%;

the croscarmellose sodium is in an amount of about 33.33 wt-%;

the mannitol is in an amount of about 16.7 wt-%; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount of about 16.7 wt-%.

14 . The pharmaceutical composition of claim 4 , wherein:

the at least one compound is in an amount ranging from about 30 mg to about 130 mg;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount ranging from about 30 mg to about 130 mg;

the croscarmellose sodium is in amount ranging from about 50 mg to about 250 mg;

the mannitol is in an amount ranging from about 30 mg to about 130 mg; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount ranging from about 30 mg to about 130 mg.

15 . (canceled)

16 . The pharmaceutical composition of claim 14 , wherein:

the at least one compound is in an amount of about 80 mg;

the Kollidon VA 64 (copovidone/vinylpyrrolidone-vinyl acetate copolymer) is in an amount of about 80 mg;

the croscarmellose sodium is in an amount of about 160 mg;

the mannitol is in an amount of about 80 mg; and

the Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) is in an amount of about 80 mg.

17 - 18 . (canceled)

19 . The pharmaceutical composition of claim 1 , wherein:

the at least one binder is partially hydrolyzed polyvinyl alcohol;

the at least one disintegrant is selected from sodium carboxymethyl starch and low substituted hydroxypropylcellulose;

the at least one filler is microcrystalline cellulose; and

the at least one lubricant is magnesium stearate.

20 . The pharmaceutical composition of claim 19 , wherein:

the at least one compound is in an amount ranging from about 25 wt-% to about 75 wt-%;

the partially hydrolyzed polyvinyl alcohol is in an amount ranging from about 0.5 wt-% to about 5 wt-%;

the low substituted hydroxypropylcellulose is in an amount ranging from about 5 wt-% to about 25 wt-%;

the microcrystalline cellulose is in an amount ranging from about 15 wt-% to about 45 wt-%; and

the magnesium stearate is in an amount ranging from about 0.1 wt-% to about 2 wt-%.

21 . (canceled)

22 . The pharmaceutical composition of claim 20 , wherein:

the at least one compound is in an amount of about 50.0 wt-%;

the partially hydrolyzed polyvinyl alcohol is in an amount of about 3.0 wt-%;

the low substituted hydroxypropylcellulose is in an amount of about 15.0 wt-%;

the microcrystalline cellulose is in an amount of about 31.0 wt-%; and

the magnesium stearate is in an amount of about 1.0 wt-%.

23 . The pharmaceutical composition of claim 19 , wherein:

the at least one compound is in an amount ranging from about 30 mg to about 130 mg;

the partially hydrolyzed polyvinyl alcohol is in an amount ranging from about 3 mg to about 6 mg;

the low substituted hydroxypropylcellulose is in an amount ranging from about 16 mg to about 32 mg;

the microcrystalline cellulose is in an amount ranging from about 35 mg to about 65 mg; and

the magnesium stearate is in an amount ranging from about 0.5 mg to about 2 mg.

24 . (canceled)

25 . The pharmaceutical composition of claim 23 , wherein:

the at least one compound is in an amount of about 80.0 mg;

the partially hydrolyzed polyvinyl alcohol is in an amount of about 4.8 mg;

the low substituted hydroxypropylcellulose is in an amount of about 24.0 mg;

the microcrystalline cellulose is in an amount of about 49.6 mg; and

the magnesium stearate is in an amount of about 1.6 mg.

26 . The pharmaceutical composition of claim 1 , further comprising sodium lauryl sulfate in an amount ranging from about 0.1 wt-% to about 2 wt-% relative to the amount of about the compound.

27 . The pharmaceutical composition of claim 1 , wherein:

the at least one compound is in an amount ranging from about 20 wt-% to about 80 wt-%;

the sodium lauryl sulfate is in an amount ranging from about 0.1 wt-% to about 2 wt-%;

the partially hydrolyzed polyvinyl alcohol is in an amount ranging from about 0.5 wt-% to about 3 wt-%;

the low substituted hydroxypropylcellulose is in an amount ranging from about 5 wt-% to about 25 wt-%;

the sodium carboxymethyl starch is in an amount ranging from about 1 wt-% to about 7 wt-%;

the microcrystalline cellulose is in an amount ranging from about 15 wt-% to about 40 wt-%; and

the magnesium stearate is in an amount ranging from about 0.1 wt-% to about 2 wt-%.

28 . (canceled)

29 . The pharmaceutical composition of claim 1 , wherein:

the at least one compound is in an amount of about 50.0 wt-%;

the sodium lauryl sulfate is in an amount of about 0.5 wt-%;

the partially hydrolyzed polyvinyl alcohol is in an amount of about 2.0 wt-%;

the low substituted hydroxypropylcellulose is in an amount of about 15.0 wt-%;

the sodium carboxymethyl starch is in an amount of about 4.0 wt-%;

the microcrystalline cellulose is in an amount of about 27.5 wt-%; and

the magnesium stearate is in an amount of about 1.0 wt-%.

30 . The pharmaceutical composition of claim 1 , wherein:

the at least one compound is in an amount ranging from about 30 mg to about 130 mg;

the sodium lauryl sulfate is in an amount ranging from about 0.1 mg to about 2 mg;

the partially hydrolyzed polyvinyl alcohol is in an amount ranging from about 1 mg to about 5 mg;

the low substituted hydroxypropylcellulose is in an amount ranging from about 10 mg to about 40 mg;

the sodium carboxymethyl starch is in an amount ranging from about 4 mg to about 9 mg;

the microcrystalline cellulose is in an amount ranging from about 30 mg to about 60 mg; and

the magnesium stearate is in an amount ranging from about 0.5 mg to about 2 mg.

31 . (canceled)

32 . The pharmaceutical composition of claim 30 , wherein:

the at least one compound is in an amount of about 80.0 mg;

the sodium lauryl sulfate is in an amount of about 0.8 mg;

the partially hydrolyzed polyvinyl alcohol is in an amount of about 3.2 mg;

the low substituted hydroxypropylcellulose is in an amount of about 24.0 mg;

the sodium carboxymethyl starch is in an amount of about 6.4 mg;

the microcrystalline cellulose is in an amount of about 44.0 mg; and

the magnesium stearate is in an amount of about 1.6 mg.

33 . (canceled)

34 . A combination for treating and/or preventing cancer comprising:

(a) a first agent comprising 2-acetylnaphtho[2,3-b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate any of the foregoing; and

(b) at least one second agent, wherein the at least one second agent is a metabolic inhibitor, a transporter inhibitor, and a combination thereof.

35 - 50 . (canceled)

51 . A method of treating cancer, comprising administering to a subject in need thereof, the pharmaceutical composition of claim 1 .

52 - 74 . (canceled)